Today In The News: Pfizer Inc. On An Acquisition Roll

Pfizer Inc. (NYSE:PFE) announced today that it will acquire Anacor (NASDAQ:ANAC) for US$5.2bn

After terminating two mega deals in a row (the failed hostile takeover of AstraZeneca (LON:AZN) and the blocked merger with Allergan (NYSE:AGN)), Pfizer Inc.┬áis back at the acquisition table, this time with a less financially ambitious target, Anacor Pharmaceuticals. The main strategic reason for the purchase is crisaborole, a product developed by Anacor that treats eczema. Continue reading “Today In The News: Pfizer Inc. On An Acquisition Roll”